43,168 Shares in Laboratory Corporation of America Holdings (LH) Purchased by OxFORD Asset Management LLP

OxFORD Asset Management LLP acquired a new stake in shares of Laboratory Corporation of America Holdings (NYSE:LH) during the third quarter, according to its most recent filing with the SEC. The fund acquired 43,168 shares of the medical research company’s stock, valued at approximately $6,454,000.

Several other large investors also recently added to or reduced their stakes in the stock. New Amsterdam Partners LLC NY raised its stake in shares of Laboratory Corporation of America by 0.7% during the 2nd quarter. New Amsterdam Partners LLC NY now owns 3,847 shares of the medical research company’s stock valued at $593,000 after purchasing an additional 27 shares during the period. Fiduciary Financial Services of The Southwest Inc. TX increased its stake in Laboratory Corporation of America by 2.3% in the 2nd quarter. Fiduciary Financial Services of The Southwest Inc. TX now owns 2,200 shares of the medical research company’s stock worth $339,000 after acquiring an additional 50 shares during the last quarter. First Allied Advisory Services Inc. increased its stake in Laboratory Corporation of America by 2.6% in the 2nd quarter. First Allied Advisory Services Inc. now owns 3,033 shares of the medical research company’s stock worth $462,000 after acquiring an additional 78 shares during the last quarter. Sentry Investment Management LLC increased its stake in Laboratory Corporation of America by 1.0% in the 2nd quarter. Sentry Investment Management LLC now owns 7,756 shares of the medical research company’s stock worth $1,196,000 after acquiring an additional 78 shares during the last quarter. Finally, Financial Counselors Inc. increased its stake in Laboratory Corporation of America by 5.9% in the 2nd quarter. Financial Counselors Inc. now owns 1,641 shares of the medical research company’s stock worth $253,000 after acquiring an additional 92 shares during the last quarter. Institutional investors own 91.45% of the company’s stock.

A number of equities analysts have weighed in on the company. ValuEngine upgraded Laboratory Corporation of America from a “hold” rating to a “buy” rating in a research note on Thursday, November 30th. Mizuho set a $165.00 target price on Laboratory Corporation of America and gave the stock a “neutral” rating in a research note on Friday. Robert W. Baird restated a “hold” rating and issued a $166.00 target price on shares of Laboratory Corporation of America in a research note on Tuesday, October 17th. KeyCorp restated a “hold” rating on shares of Laboratory Corporation of America in a research note on Tuesday, September 26th. Finally, Zacks Investment Research lowered Laboratory Corporation of America from a “buy” rating to a “hold” rating in a research note on Tuesday, September 26th. Six research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. Laboratory Corporation of America has a consensus rating of “Buy” and an average price target of $170.92.

In other news, CEO David P. King sold 44,687 shares of the stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $156.86, for a total transaction of $7,009,602.82. Following the transaction, the chief executive officer now directly owns 258,753 shares in the company, valued at approximately $40,587,995.58. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Dwight Gary Gilliland sold 971 shares of the stock in a transaction dated Monday, October 30th. The shares were sold at an average price of $153.52, for a total value of $149,067.92. Following the transaction, the director now owns 3,501 shares in the company, valued at $537,473.52. The disclosure for this sale can be found here. 0.90% of the stock is currently owned by corporate insiders.

Shares of Laboratory Corporation of America Holdings (NYSE:LH) traded up $1.42 during trading on Tuesday, hitting $157.91. The stock had a trading volume of 812,200 shares, compared to its average volume of 723,702. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.89 and a quick ratio of 1.75. The company has a market cap of $15,930.68, a price-to-earnings ratio of 16.83, a PEG ratio of 1.66 and a beta of 0.87. Laboratory Corporation of America Holdings has a 12-month low of $123.41 and a 12-month high of $164.22.

Laboratory Corporation of America (NYSE:LH) last announced its quarterly earnings data on Wednesday, October 25th. The medical research company reported $2.46 EPS for the quarter, beating the consensus estimate of $2.38 by $0.08. The firm had revenue of $2.60 billion for the quarter, compared to analyst estimates of $2.55 billion. Laboratory Corporation of America had a return on equity of 16.75% and a net margin of 7.40%. The company’s revenue was up 9.5% on a year-over-year basis. During the same period in the prior year, the company earned $2.25 EPS. analysts expect that Laboratory Corporation of America Holdings will post 9.52 EPS for the current year.

WARNING: This report was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another domain, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be accessed at https://www.dispatchtribunal.com/2017/12/05/43168-shares-in-laboratory-corporation-of-america-holdings-lh-purchased-by-oxford-asset-management-llp.html.

Laboratory Corporation of America Company Profile

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Laboratory Corporation of America Holdings (NYSE:LH).

Institutional Ownership by Quarter for Laboratory Corporation of America (NYSE:LH)

Receive News & Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply